Revance Therapeutics (RVNC) Competitors

Harrow has a net margin of -1.89% compared to Revance Therapeutics' net margin of -74.67%. Harrow's return on equity of 36.51% beat Revance Therapeutics' return on equity.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revance Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.

In the previous week, Harrow had 4 more articles in the media than Revance Therapeutics. MarketBeat recorded 4 mentions for Harrow and 0 mentions for Revance Therapeutics. Harrow's average media sentiment score of 0.60 beat Revance Therapeutics' score of 0.00 indicating that Harrow is being referred to more favorably in the news media.

Harrow has a consensus target price of $69.86, suggesting a potential upside of 72.49%. Given Harrow's stronger consensus rating and higher possible upside, analysts plainly believe Harrow is more favorable than Revance Therapeutics.

Harrow has higher revenue and earnings than Revance Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Damora Therapeutics, Inc. Common Stock's return on equity.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 10.5% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revance Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

In the previous week, Damora Therapeutics, Inc. Common Stock had 3 more articles in the media than Revance Therapeutics. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 0 mentions for Revance Therapeutics. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat Revance Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.

Damora Therapeutics, Inc. Common Stock has a consensus target price of $43.40, suggesting a potential upside of 74.51%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Revance Therapeutics.

Damora Therapeutics, Inc. Common Stock has lower revenue, but higher earnings than Revance Therapeutics. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Revance Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.

In the previous week, Ardelyx had 23 more articles in the media than Revance Therapeutics. MarketBeat recorded 23 mentions for Ardelyx and 0 mentions for Revance Therapeutics. Ardelyx's average media sentiment score of 0.28 beat Revance Therapeutics' score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Ardelyx has a consensus target price of $15.70, suggesting a potential upside of 120.20%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Revance Therapeutics.

Ardelyx has higher revenue and earnings than Revance Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Ardelyx has a net margin of -13.58% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Ardelyx's return on equity.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 4.8% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Immunocore had 5 more articles in the media than Revance Therapeutics. MarketBeat recorded 5 mentions for Immunocore and 0 mentions for Revance Therapeutics. Immunocore's average media sentiment score of 0.28 beat Revance Therapeutics' score of 0.00 indicating that Immunocore is being referred to more favorably in the news media.

Revance Therapeutics has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Immunocore has higher revenue and earnings than Revance Therapeutics. Immunocore is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Immunocore has a consensus target price of $60.89, suggesting a potential upside of 111.13%. Given Immunocore's stronger consensus rating and higher probable upside, analysts plainly believe Immunocore is more favorable than Revance Therapeutics.

Immunocore has a net margin of -8.88% compared to Revance Therapeutics' net margin of -74.67%. Revance Therapeutics' return on equity of 0.00% beat Immunocore's return on equity.

97.7% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 5.1% of Revance Therapeutics shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.